Hosted by Tonacea, The first China Pharmaceutical Innovation Conference (CPIC 2026) will be grandly held at the National Exhibition and Convention Center (Shanghai) from July 22 to 24, 2026.

Modelled after the J.P. Morgan Healthcare Conference, CPIC pioneers a brand-new paradigm featuring China-driven innovation, global transformation and Shanghai-centered transactions. Serving as a premier gateway for overseas capital and enterprises to understand China’s pharmaceutical innovation ecosystem, as well as a core hub for Chinese pharmaceutical firms to expand globally and connect with international partners, CPIC is poised to become the annual benchmark event for investment and cooperation in the healthcare industry.The conference will feature dozens of special sessions，covering a wide range of hot topics and future directions in healthcare innovation investment and globalization.

From lab to industrialization, from original innovation to global collaboration – the University of Science and Technology of China (USTC), as one of the major cradles of basic research and frontier technology in China，is nurturing the next breakthroughs in biopharmaceutical with its rich academic legacy and innovative genes.

The agenda of the “USTC / China-Japan Pharmaceutical & New Materials Innovation Special Session – USTC’s Original Innovation Power” is officially released today.

Gathering USTC’s core original innovation forces, this special session focuses on antibody and small-molecule R&D, while deeply connecting technology platforms, CDMOs, legal services, and other industrial support ecosystems to facilitate China-Japan collaboration in pharmaceuticals and new materials.

July 22 to 24,National Exhibition and Convention Center (Shanghai) . We hope to align with USTC’s innovative forces and jointly explore the journey of original innovation for new drug research and development.

Session Agenda
Session Co-organizer: USTC Alumni

Session Planner: Yonghan Hu, Deputy General Manager & CTO, Evopoint Bio

13:00–13:05 Opening Remarks 
Jingyu Li,Founder & CEO,Cellatopia

Part I: Antibody & Small Molecule New Drug R&D

13:05-13:25 Insights from the Development of GIPR/GLP-1R Bispecific Molecule AMG133: Mechanisms, Applications, and Case Studies of Peptide-Drug Conjugates
Junmin Ye, CSO, Salubris

13:25-13:45　Nanobody Drug Development: Strategies, Case Studies, and Trends
Tengchuan Jin, Professor, USTC Life Sciences and Medicine ; Investigator, State Key Laboratory of Immune Response and Immunotherapy

13:45-14:05 mRNA-Encoded Antibodies: Targeted Delivery Ushers in a New Era of Precision Immunotherapy
Congcong Xu, Professor, College of Pharmaceutical Sciences, Soochow University

14:05-14:25　Developing Bifunctional PROTACs to Address Undruggable Targets
Shaoyun Xiang, Founder & CEO, Polymed

14:25-14:45 Remodeling CNS Drug Discovery: A Transformative Era of Central Nervous System Drug R&D
Xuechu Zhen, Professor, College of Pharmaceutical Sciences, Soochow University

14:45-15:05　Coffee Break

Part II: New Drug Services (Technology Platforms, CDMO, Legal, etc.)

15:05-15:25　AI-Driven Cell Therapy and Regenerative Medicine: Current Status, Challenges, and Future Pathways
Jingyu Li,Founder & CEO,Cellatopia

15:25-15:45　Opportunities and Challenges of Domestic Substitution in Biopharma
Zhi Li, CEO, Intellective Bio

15:45-16:05　3D Micro-tissue Technology: Bridging In Vivo and In Vitro, Reshaping Preclinical Drug Development
Hongda Sheng, Vice President, Hepobio

16:05-16:25　From Project Initiation to Commercial Launch: A Full Landscape of U.S. Litigation Risks for Biopharmaceutical Enterprises
Yingli Wang, Partner, Perkins Coie LLP

16:25-17:05　Panel Discussion：USTC’s Original Innovation – Biopharmaceutical  Innovation and Industry-Academia-Research Translation in the AI Era

Haiyang Wei (Moderator), Vice President,Evopoint Bio
Shaoyun Xiang, Founder & CEO, Polymed
Yonghan Hu, Deputy General Manager & CTO, Evopoint Bio
Junmin Ye, CSO, Salubris
Yingli Wang, Partner, Perkins Coie LLP
Tengchuan Jin, Professor, USTC Life Sciences and Medicine ; Investigator, State Key Laboratory of Immune Response and Immunotherapy
Rongkuan Hu, CEO,Starna

17:05-17:10　Summary & Closing
Jingyu Li,Founder & CEO,Cellatopia